Theoretical and Natural Science
- The Open Access Proceedings Series for Conferences
Theoretical and Natural Science
Vol. 29, 16 January 2024
Open
Access | Article
Current available treatments for NSCLC
* Author to whom correspondence should be addressed.
Abstract
Lung cancer is one of the most prominent forms of cancer and ranks as the deadliest of disease afflicting humanity. To tackle this issue, a variety of treatment approaches have been devised to counteract this disease. This review aims to illustrate the mainstream curative and palliative treatment methods in managing non-small cell lung cancer, the most common subtype of lung malignancies.For each treatment method, we have investigated its mechanism, classifications, and techniques involved as well as the clinical success of these treatments. Furthermore, we have also included the reasoning behind each treatment plan, including both quality of life as well as overall survival benefits for the patient.
Keywords
Non-small cell lung cancer, Therapeutic Vaccination, Molecularly Targeted Therapy, Tyrosine Kinase Inhibitors, Immunotherapy
References
1. Lackey, A., & Donington, J. (2013). Surgical Management of Lung Cancer. Seminars in Interventional Radiology, 30(02), 133–140. https://doi.org/10.1055/s-0033-1342954
2. Darling, G. E., Allen, M. S., Decker, P. A., Ballman, K., Malthaner, R. A., Inculet, R. I., Jones, D. R., McKenna, R. J., Landreneau, R. J., Rusch, V. W., & Putnam, J. B. (2011). Randomized trial of mediastinal lymph node sampling versus complete lymphadenectomy during pulmonary resection in the patient with N0 or N1 (less than hilar) non–small cell carcinoma: Results of the American College of Surgery Oncology Group Z0030 Trial. The Journal of Thoracic and Cardiovascular Surgery, 141(3), 662–670. https://doi.org/10.1016/j.jtcvs.2010.11.008
3. Ziarnik, E., & Grogan, E. L. (2015). Postlobectomy Early Complications. Thoracic Surgery Clinics, 25(3), 355–364. https://doi.org/10.1016/j.thorsurg.2015.04.003
4. Hoy, H., Lynch, T., & Beck, M. (2019). Surgical Treatment of Lung Cancer. Critical Care Nursing Clinics of North America, 31(3), 303–313. https://doi.org/10.1016/j.cnc.2019.05.002
5. Nagasaka, M., & Gadgeel, S. M. (2017). Role of chemotherapy and targeted therapy in early-stage non-small cell lung cancer. Expert Review of Anticancer Therapy, 18(1), 63–70. https://doi.org/10.1080/14737140.2018.1409624
6. Schrank, Z., Chhabra, G., Lin, L., Iderzorig, T., Osude, C., Khan, N., Kuckovic, A., Singh, S., Miller, R., & Puri, N. (2018). Current Molecular-Targeted Therapies in NSCLC and Their Mechanism of Resistance. Cancers, 10(7), 224. https://doi.org/10.3390/cancers10070224
7. Duma, N., Santana-Davila, R., & Molina, J. R. (2019). Non–Small Cell Lung Cancer: Epidemiology, Screening, Diagnosis, and Treatment. Mayo Clinic Proceedings, 94(8), 1623–1640. https://doi.org/10.1016/j.mayocp.2019.01.013
8. Johnson, M., Chiara Garassino, M., Mok, T., & Mitsudomi, T. (2022). Treatment Strategies and Outcomes for Patients with EGFR-mutant Non-Small Cell Lung Cancer Resistant to EGFR Tyrosine Kinase Inhibitors: Focus on Novel Therapies. Lung Cancer, 170. https://doi.org/10.1016/j.lungcan.2022.05.011
9. Jonna, S., & Subramaniam, D. S. (2019). Molecular Diagnostics and Targeted Therapies in Non-small Cell Lung Cancer (NSCLC): An Update. Discovery Medicine, 27(148), 167–170. https://www.discoverymedicine.com/Sushma-Jonna/2019/03/molecular-diagnostics-and-targeted-therapies-in-non-small-cell-lung-cancer-nsclc-an-update/
10. Cortés-Jofré, M., Uranga, R., Torres Pombert, A., Arango Prado, M. del C., Caballero Aguirrechu, I., Pacheco, C., Ortiz Reyes, R. M., Chuecas, F., & Mas Bermejo, P. I. (2019). Therapeutic vaccines for advanced non-small cell lung cancer. Cochrane Database of Systematic Reviews. https://doi.org/10.1002/14651858.cd013377
11. García-Pardo, M., Gorria, T., Malenica, I., Corgnac, S., Teixidó, C., & Mezquita, L. (2022). Vaccine Therapy in Non-Small Cell Lung Cancer. Vaccines, 10(5), 740. https://doi.org/10.3390/vaccines10050740
12. Hirsch, F. R., Scagliotti, G. V., Mulshine, J. L., Kwon, R., Curran, W. J., Wu, Y.-L., & Paz-Ares, L. (2017). Lung cancer: current therapies and new targeted treatments. The Lancet, 389(10066), 299–311. https://doi.org/10.1016/s0140-6736(16)30958-8
Data Availability
The datasets used and/or analyzed during the current study will be available from the authors upon reasonable request.
This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License. Authors who publish this series agree to the following terms:
1. Authors retain copyright and grant the series right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgment of the work's authorship and initial publication in this series.
2. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the series's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial publication in this series.
3. Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See Open Access Instruction).
- Volume Title
- Proceedings of the 2nd International Conference on Modern Medicine and Global Health
- ISBN (Print)
- 978-1-83558-279-4
- ISBN (Online)
- 978-1-83558-280-0
- Published Date
- 16 January 2024
- Series
- Theoretical and Natural Science
- ISSN (Print)
- 2753-8818
- ISSN (Online)
- 2753-8826
- DOI
- 10.54254/2753-8818/29/20240638
- Copyright
- 16 January 2024
- Open Access
- This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited